Oct 29, 2014

Adynxx to present at ASRA Conference on November 14th, 2014

SAN FRANCISCO, CALIF., October 29, 2014 – Don Manning, chief medical officer, will present at the 13th Annual Pain Medicine Meeting, presented by the American Society of Regional Anesthesia and Pain Medicine on November 14th, 2014, at the Hyatt Regency, San Francisco. Dr. Manning will present an abstract entitled ADYX002: Phase 2a Study to Evaluate Safety and Efficacy of a Preoperative Dose of Transcription Factor Decoy AYX1 to Prevent Pain After Total Knee Arthroplasty,” during a moderated e-poster discussion session from 8am to 930am.  Additionally, ASRA selected the abstract as a Best of Meeting award winner, and Dr. Manning will present the abstract during the Excellence in ASRA Awards Luncheon from 12:15 – 2:15pm.

 About Adynxx

Adynxx, located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.

Adynxx’s lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at the time of surgery. Funded by Domain Associates, Adynxx has successfully completed a safety Phase 1 and a proof-of-concept phase 2 clinical study of AYX1. Additional AYX drug candidate compounds designed to address a range of intractable neuropathic and inflammatory pain syndromes are also in active development.